Division of Cardiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy.
European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Front Immunol. 2022 Aug 25;13:958418. doi: 10.3389/fimmu.2022.958418. eCollection 2022.
To investigate the clinical predictors of in-hospital mortality in hospitalized patients with Coronavirus disease 2019 (COVID-19) infection during the Omicron period.
All consecutive hospitalized laboratory-confirmed COVID-19 patients between January and May 2022 were retrospectively analyzed. All patients underwent accurate physical, laboratory, radiographic and echocardiographic examination. Primary endpoint was in-hospital mortality.
74 consecutive COVID-19 patients (80.0 ± 12.6 yrs, 45.9% males) were included. Patients who died during hospitalization (27%) and those who were discharged alive (73%) were separately analyzed. Compared to patients discharged alive, those who died were significantly older, with higher comorbidity burden and greater prevalence of laboratory, radiographic and echographic signs of pulmonary and systemic congestion. Charlson comorbidity index (CCI) (OR 1.76, 95%CI 1.07-2.92), neutrophil-to-lymphocyte ratio (NLR) (OR 1.24, 95%CI 1.10-1.39) and absence of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) therapy (OR 0.01, 95%CI 0.00-0.22) independently predicted the primary endpoint. CCI ≥7 and NLR ≥9 were the best cut-off values for predicting mortality. The mortality risk for patients with CCI ≥7, NLR ≥9 and not in ACEI/ARBs therapy was high (86%); for patients with CCI <7, NLR ≥9, with (16.6%) or without (25%) ACEI/ARBs therapy was intermediate; for patients with CCI <7, NLR <9 and in ACEI/ARBs therapy was of 0%.
High comorbidity burden, high levels of NLR and the undertreatment with ACEI/ARBs were the main prognostic indicators of in-hospital mortality. The risk stratification of COVID-19 patients at hospital admission would help the clinicians to take care of the high-risk patients and reduce the mortality.
探讨奥密克戎变异株流行期间住院 2019 年冠状病毒病(COVID-19)感染患者住院期间院内死亡的临床预测因素。
回顾性分析 2022 年 1 月至 5 月期间连续住院的实验室确诊 COVID-19 患者。所有患者均接受了准确的体格、实验室、影像学和超声心动图检查。主要终点为院内死亡率。
共纳入 74 例连续 COVID-19 患者(80.0±12.6 岁,45.9%为男性)。分别分析了住院期间死亡(27%)和存活出院(73%)的患者。与存活出院的患者相比,死亡患者年龄更大,合并症负担更高,肺部和全身充血的实验室、影像学和超声心动图征象更为常见。Charlson 合并症指数(CCI)(OR 1.76,95%CI 1.07-2.92)、中性粒细胞与淋巴细胞比值(NLR)(OR 1.24,95%CI 1.10-1.39)和未使用血管紧张素转换酶抑制剂(ACEI)/血管紧张素 II 受体阻滞剂(ARB)治疗(OR 0.01,95%CI 0.00-0.22)独立预测主要终点。CCI≥7 和 NLR≥9 是预测死亡率的最佳截断值。CCI≥7、NLR≥9 且未使用 ACEI/ARB 治疗的患者死亡率高(86%);CCI<7、NLR≥9 且使用(16.6%)或未使用(25%)ACEI/ARB 治疗的患者死亡率居中;CCI<7、NLR<9 且使用 ACEI/ARB 治疗的患者死亡率为 0%。
高合并症负担、高 NLR 水平和 ACEI/ARB 治疗不足是住院期间死亡率的主要预后指标。COVID-19 患者入院时的风险分层有助于临床医生照顾高危患者并降低死亡率。